(Q43506664)

English

Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype

scientific article published in August 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

0 references

author name string

B J Lipworth

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

O J Dempsey

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

I Aziz

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

A M Wilson

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

language of work or name

0 references

publication date

1 August 2000

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

American Journal of Medicine

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

109

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

114-121

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

The glutamine 27 β-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Leukotriene-receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Measurement of airway responsiveness to methacholine: relative importance of the precision of drug delivery and the method of assessing response

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Dosage and time effects of inhaled budesonide on bronchial hyperreactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Measuring exhaled nitric oxide: not only a matter of how--but also why--should we do it?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

NO in Exhaled Air of Asthmatic Children Is Reduced by the Leukotriene Receptor Antagonist Montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Effects of treatment with formoterol on bronchoprotection against methacholine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900454-X

7 January 2021

Identifiers

10.1016/S0002-9343(00)00454-X

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43506664&oldid=1990196416"